ENANTA PHARMACEUTICALS, INC Operating Lease, Liability, Current
ENANTA PHARMACEUTICALS, INC (ENTA) had Operating Lease, Liability, Current of $3.91 million as of 2026-06-30, per its 10-Q filed 2026-08-12.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseLiabilityCurrent · last filed 2026-08-12
- 2026-06-30: Operating Lease, Liability, Current $3.91M.
- 2026-03-31: Operating Lease, Liability, Current $3.76M.
- 2025-12-31: Operating Lease, Liability, Current $3.29M.
- 2025-09-30: Operating Lease, Liability, Current $3.15M.
| Period end | Operating Lease, Liability, Current |
|---|---|
| 2026-06-30 | $3.91M 10-Q · filed 2026-08-12 |
| 2026-03-31 | $3.76M 10-Q · filed 2026-05-13 |
| 2025-12-31 | $3.29M 10-Q · filed 2026-02-11 |
| 2025-09-30 | $3.15M 10-Q · filed 2026-08-12 |
| 2025-06-30 | $2.39M 10-Q · filed 2025-08-13 |
| 2025-03-31 | $2.20M 10-Q · filed 2025-05-14 |
| 2024-12-31 | $1.01M 10-Q · filed 2025-02-12 |
| 2024-09-30 | $1.52M 10-K · filed 2025-11-19 |
| 2024-06-30 | $2.43M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $3.58M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $4.97M 10-Q · filed 2024-02-08 |
| 2023-09-30 | $5.28M 10-K · filed 2024-11-27 |
| 2023-06-30 | $5.37M 10-Q · filed 2023-08-08 |
| 2023-03-31 | $4.92M 10-Q · filed 2023-05-09 |
| 2022-12-31 | $3.49M 10-Q · filed 2023-02-08 |
| 2022-09-30 | $2.89M 10-K · filed 2023-11-22 |
| 2022-06-30 | $2.60M 10-Q · filed 2022-08-08 |
| 2022-03-31 | $3.01M 10-Q · filed 2022-05-09 |
| 2021-12-31 | $3.47M 10-Q · filed 2022-02-10 |
| 2021-09-30 | $4.20M 10-K · filed 2022-11-23 |
| 2021-06-30 | $5.03M 10-Q · filed 2021-08-09 |
| 2021-03-31 | $5.17M 10-Q · filed 2021-05-10 |
| 2020-12-31 | $5.20M 10-Q · filed 2021-02-09 |
| 2020-09-30 | $4.26M 10-K · filed 2021-11-24 |
| 2020-06-30 | $4.26M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $3.76M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $3.13M 10-Q · filed 2020-02-10 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Emergent BioSolutions Inc. (EBS) | United States | $0.347B | -2.43 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |